Home Biosimilar Antibodies Immunology & Inflammation CD markers Efalizumab (Anti-Integrin aL / ITGAL / CD11a)
For research use only. Not for use in humans.

Efalizumab (Anti-Integrin aL / ITGAL / CD11a)

Synonyms: CD11A,ITGAL

Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD.

Efalizumab (Anti-Integrin aL / ITGAL / CD11a)

Quality Control

Batch: A242101 Purity: 99% Protein concentration: 18.41mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD.

Product Details

CAS No. 214745-43-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00276250 COMPLETED Drug: Efalizumab|Drug: Abatacept|Drug: Belatacept Type 1 Diabetes Mellitus Emory University 2005-12 PHASE2
NCT00672204 TERMINATED Drug: Raptiva|Drug: Sirolimus|Drug: anti-thymocyte globulin Type 1 Diabetes Mellitus; Hypoglycemia University of Minnesota 2007-11 PHASE1; PHASE2
NCT00737763 WITHDRAWN Drug: efalizumab|Drug: placebo Diabetes Mellitus, Type 1 Emory University 2008-10 PHASE2
NCT00707070 UNKNOWN Drug: efalizumab plus placebo|Drug: efalizumab plus acitreti Chronic Plaque Psoriasis Universita di Verona 2008-09 PHASE4
NCT00746980 WITHDRAWN Drug: efalizumab Alopecia Totalis Northwestern University 2008-08 PHASE2
NCT00739882 TERMINATED Drug: Efalizumab - anti CD11a recombinant human monoclonal a Chronic Plaque Psoriasis Merck KGaA, Darmstadt, Germany 2008-04 PHASE4

(data from https://clinicaltrials.gov, updated on 2016-07-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.